ADIL | tickerfilter.com

Fundamental analysis

37%

Profitability 35%

Dept financing 24%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-9.49%

1 Month

1,360.46%

3 Months

602.02%

6 Months

561.09%

1 Year

205.29%

2 Year

-16.73%

Key data

Stock price

$2.29

P/E Ratio

0.00

DAY RANGE

$2.16 - $2.50

EPS

-$1.03

52 WEEK RANGE

$0.13 - $3.67

52 WEEK CHANGE

$197.40

MARKET CAP

7.838 M

YIELD

N/A

SHARES OUTSTANDING

23.988 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-12-2025

BETA

0.84

PUBLIC FLOAT

AVERAGE 10 VOLUME

$287,869

AVERAGE 30 VOLUME

$389,484

Company detail

CEO: Cary J. Claiborne
Region: US
Website: adialpharma.com
Employees: 20
IPO year: 2018

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction.

ADIL - ADIAL PHARMACEUTICALS, INC.